Login

Brukernavn

Passord

REDUCED RISK FOR CELEBRAL EMBOLI
Outflow to descending aorta and pulsed flow.

NEW PATIENT POPULATION
A unique technology offers treatment for both patients for preserved and reduced Ejection Fraction.

PULSATILE
Pulsatile flow, syncronized to the heart rythm. Reduced risk of aortic regurgitation, GI bleed.

ABOUT US

Northern Development was founded in 2014 with the objective of developing the next generation of heart-assist device.

It has one of the most experienced development teams in the market with more than 100 years accumulated experience in the development and use of VADs.

Northern Development has Head office in Oslo, Norway.

In 2016, Northern Research were established as a subsidiary company, designing the PulseVAD components. Northern Research is located in Sydney, Australia, where we have office and research facilities.

Northern Research is headed by John Begg, Chief Technical Officer, and Peter Ayre, Chief R &D.

Partners for our program are Norwegian Research Counsil, Innovation Norway, Oslo University Hospital and University of New South Wales.

TECHNOLOGY

PulseVad is the first generation Smart pump coming to the market.

PulseVad provides adaptive and pulsatile flow, syncronized to the heart, using new sensor technology. The pump has adaptive flow according to patient physiological need.
The pulsed flow and pump design reduce the risk of thrombus formation and risk of celebral emboli.

PulseVad will be implanted minimally invasive and off pump, with a special designed system for access and placement.

Smart pump
Syncronized flow – Minimal Invasive implant – Adaptive to patients needs – Route LA to DA – Thrombus minimalization

MARKET

Total market potential for long-term assist devices is estimated to be
approx 160.000 pcs, with a 50/50 split between patients with preserved and reduced EF.

Currently no medical treatment is offered to patients with preserved EF, and where PulseVad will offer a break through technology when introduced in the market.

PulseVad will also offer treatment options for the traditional VAD patient with reduced EF.

CONTACT

Name
Email
Message

For further enquiries, please send mail to :
info@northerndevelop.com